Restrictive chronic lung allograft dysfunction: Where are we now?
Evidence level: narrative perspective; abstract-only
A 2015 perspective reviewing what was known about restrictive CLAD, including diagnosis, imaging, pathology, prognosis and gaps.
As of . Primary source: Publisher record via DOI.
Summary
This perspective article reviews the evidence for the restrictive phenotype of CLAD (rCLAD). According to the abstract, rCLAD occurs in approximately 30 percent of CLAD patients and is characterised by a restrictive lung function pattern with persistent decline in FEV1, forced vital capacity and total lung capacity, persistent parenchymal infiltrates and subpleural thickening on chest CT, and pleuroparenchymal fibroelastosis and obliterative bronchiolitis on histopathology. The abstract reports median survival after diagnosis of 6 to 18 months, compared with 3 to 5 years for BOS. The article also reviews diagnostic criteria, risk factors and mechanisms, and lists opportunities for further research, including a need for adequate therapy. Only the abstract was read.
Details
- doi
- 10.1016/j.healun.2014.11.007
- pmid
- 25577564
- authors
- Verleden SE, Ruttens D, Vandermeulen E, Bellon H, Van Raemdonck DE, Dupont LJ, Vanaudenaerde BM, Verleden G, Vos R
- journal
- The Journal of Heart and Lung Transplantation
- year
- 2015
- volume
- 34
- issue
- 5
- pages
- 625-630
Sources and links
- Publisher record via DOI (primary)
- PubMed 25577564
Related
Links from this record
- reviews: Restrictive allograft syndrome (RAS)
- compares with: Bronchiolitis obliterans syndrome (BOS)
Known gaps in this record
- full text not read (abstract only)
- funding statement and grant numbers
- author affiliations
Information resource only. Not medical advice. Not a substitute for the care of the patient's transplant team.